登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，3月10日，In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-11

  • In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein

    Mandana Behbahani

    doi: https://doi.org/10.1101/2020.03.10.985499

    Abstract

    It is of special significance to find a safe and effective vaccine against coronavirus disease 2019 (COVID-19) that can induce T cell and B cell -mediated immune responses. There is currently no vaccine to prevent COVID-19. In this project, a novel multi-epitope vaccine for COVID-19 virus based on surface glycoprotein was designed through application of bioinformatics methods. At the first, seventeen potent linear B-cell and T-cell binding epitopes from surface glycoprotein were predicted in silico, then the epitopes were joined together via different linkers.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.03.10.985499v1
12浏览量
原文链接
相关报告

  • 《BioRxiv，3月3日，Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2)》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-04
    • Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2) Ye Feng, Min Qiu, Shengmei Zou, Yun Li, Kai Luo, Rongchang Chen, Yingqiang Sun, Kui Wang, Xinlei Zhuang, Shanshan Zhang, Shuqing Chen, Fan Mo doi: https://doi.org/10.1101/2020.03.03.962332 Abstract A new coronavirus SARS-CoV-2, recently discovered in Wuhan, China, has caused over 74000 infection cases and 2000 deaths. Due to the rapidly growing cases and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. In the present study, we performed an in silico approach based on the available virus genome to identify the antigenic B-cell epitopes and human-leukocyte-antigen (HLA) restricted T-cell epitopes. A total of 61 B-cell epitopes were initially identified, 19 of which with higher potential immunogenicity were used for vaccine design. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    64浏览量
    原文链接

  • 《BioRxiv，2月11日，Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-12
    • Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach Miysaa I. Abdelmageed, Abdelrahman Hamza Abdelmoneim Sr., Mujahed I. Mustafa Sr., Nafisa M. Elfadol, Naseem S. Murshed, Shaza W. Shantier, Abdelrafie M. Makhawi doi: https://doi.org/10.1101/2020.02.04.934232 Abstract Background: on the late December 2019, a new endemic has been spread across Wuhan City, China; within a few weeks, a novel coronavirus designated as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization (WHO). In late January 2020, WHO declared the outbreak a public-health emergency of international concern due to the rapid spreading and increasing worldwide. There is no vaccine or approved treatment for this emerging infection; therefore, the objective of this paper is to design a multi epitope peptide vaccine against 2019-nCoV using immunoinformatics approach. Method: We will highlight a technique facilitating the combination of immunoinformatics approach with comparative genomic approach to determine our potential target for designing the T cell epitopes-based peptide vaccine using the envelope protein of 2019-nCoV as a target. Results: Extensive mutations, insertion and deletion were discovered with comparative sequencing in 2019-nCoV strain; in addition, 10 MHC1 and MHC2 related peptides were promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99% respectively. Conclusion: T cell epitopes-based peptide vaccine was designed for 2019-nCoV using envelope protein as an immunogenic target; nevertheless, the proposed T cell epitopes-based peptide vaccine rapidly needs to validates clinically to ensure its safety and immunogenic profile to assist on stopping this epidemic before it leads to devastating global outbreaks. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    37浏览量
    原文链接